Literature DB >> 25483324

A spectrum of contributions of type 2 diabetes and related metabolic characteristics to dementia.

Ramit Ravona-Springer1, Michal Schnaider Beeri2.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25483324      PMCID： PMC5753418          DOI： 10.1016/j.euroneuro.2014.11.009

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN： 0924-977X            Impact factor:   4.600


× No keyword cloud information.
  11 in total

Review 1.  Brain metabolic dysfunction at the core of Alzheimer's disease.

Authors:  Suzanne M de la Monte; Ming Tong
Journal:  Biochem Pharmacol       Date:  2013-12-28       Impact factor: 5.858

Review 2.  Prevention and treatment of type 2 diabetes: current role of lifestyle, natural product, and pharmacological interventions.

Authors:  Nicholas P Hays; Pietro R Galassetti; Robert H Coker
Journal:  Pharmacol Ther       Date:  2008-03-02       Impact factor: 12.310

Review 3.  Insulin and Alzheimer's disease: untangling the web.

Authors:  Suzanne Craft; Brenna Cholerton; Laura D Baker
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

Review 4.  2003-2013: a decade of body mass index, Alzheimer's disease, and dementia.

Authors:  Tim L Emmerzaal; Amanda J Kiliaan; Deborah R Gustafson
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 5.  Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association.

Authors:  Philip B Gorelick; Angelo Scuteri; Sandra E Black; Charles Decarli; Steven M Greenberg; Costantino Iadecola; Lenore J Launer; Stephane Laurent; Oscar L Lopez; David Nyenhuis; Ronald C Petersen; Julie A Schneider; Christophe Tzourio; Donna K Arnett; David A Bennett; Helena C Chui; Randall T Higashida; Ruth Lindquist; Peter M Nilsson; Gustavo C Roman; Frank W Sellke; Sudha Seshadri
Journal:  Stroke       Date:  2011-07-21       Impact factor: 7.914

Review 6.  Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease.

Authors:  Fernanda G De Felice; Sergio T Ferreira
Journal:  Diabetes       Date:  2014-06-15       Impact factor: 9.461

Review 7.  Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.

Authors:  Chen-Chen Tan; Jin-Tai Yu; Hui-Fu Wang; Meng-Shan Tan; Xiang-Fei Meng; Chong Wang; Teng Jiang; Xi-Chen Zhu; Lan Tan
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

8.  Risk factors for progression of brain atrophy in aging: six-year follow-up of normal subjects.

Authors:  C Enzinger; F Fazekas; P M Matthews; S Ropele; H Schmidt; S Smith; R Schmidt
Journal:  Neurology       Date:  2005-05-24       Impact factor: 9.910

9.  Diagnosis and classification of diabetes mellitus.

Authors: 
Journal:  Diabetes Care       Date:  2010-01       Impact factor: 19.112

10.  Trajectories in glycemic control over time are associated with cognitive performance in elderly subjects with type 2 diabetes.

Authors:  Ramit Ravona-Springer; Anthony Heymann; James Schmeidler; Erin Moshier; James Godbold; Mary Sano; Derek Leroith; Sterling Johnson; Rachel Preiss; Keren Koifman; Hadas Hoffman; Jeremy M Silverman; Michal Schnaider Beeri
Journal:  PLoS One       Date:  2014-06-02       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.